We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cisbio international Expands List of Serine/Threonine Kinases Validated using HTRF® KinEASE™

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Cisbio international has announced that it has expanded the list of kinases validated using its universal HTRF® KinEASE™ platform to include 34 additional kinases. 

Launched in March 2006, HTRF® KinEASE™ is a universal and sensitive assay for the screening of Serine/Threonine (Ser/Thr) kinases, major targets in drug discovery. 

With these additions, Cisbio has now validated its assay platform on 104 Ser/Thr kinases. 

HTRF® KinEASE™, developed in collaboration with Upstate USA, Inc., is based on a combination of 3 biotinylated substrates, a single proprietary monoclonal antibody and Cisbio’s patented HTRF® technology and can be used for kinase selectivity assays and high-throughput screening.

With the imminent addition of another peptide substrate, Cisbio will continue to develop this program with regular increments of validated kinases.

“The adoption of HTRF® KinEASE™ has been extraordinary since its launch,” said François Degorce, head of HTRF® marketing & business development at Cisbio.  “Clients have produced outstanding data using HTRF® KinEASE™ not only with Cisbio validated kinases, but also using Serine/Threonine kinases not previously assessed by Cisbio, attesting to the robustness of the reagents and HTRF® technology.  We strongly believe that our antibody-based kinase screening platform fulfills our customers' expectations in terms of assay reliability and sensitivity.”

In addition to HTRF® KinEASE™, Cisbio offers a line of toolbox reagents and custom labeling and assay development services for the creation of highly specific Ser/Thr and tyrosine kinase assays, all based on its HTRF® technology. 

This offers customers the ability to use a single technology for both universal and specific kinase assays.